Valneva SE (0OB3.L)
| Previous close | 20.98 |
| Open | 21.14 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 21.10 - 21.88 |
| 52-week range | 21.10 - 21.88 |
| Volume | 5,257 |
| Avg. volume | N/A |
| Market cap | 1.93B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.09 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
Saint-Herblain (France), November 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years. The agreement follows the announcement made earlier this month that the EC had approved the APA1. Under the terms of the agreement following final review of the volumes
- Globe Newswire
Valneva Reports Nine-Month 2021 Revenue and Cash
Strong financial position Cash and cash equivalents of €247.9 million at the end of September 2021 Reflects $107.6 million of gross proceeds raised in a US IPO and placement in Europe in the second quarter of 2021Does not include $102.0 million of gross proceeds raised in a follow-on offering in the US and Europe in the fourth quarter of 2021 Total revenue (excluding COVID) of €69.8 million in the first nine months of 2021 compared to €58.8 million in the first nine months of 2020 Product sales
- Globe Newswire
Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
Saint-Herblain (France), November 15, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present its Chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American Society of Tropical Medicine & Hygiene (ASTMH) 2021 Annual Meeting. Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, MD, will present on Friday, November 19 at 2:15pm ET, “Chikungunya: Phase 3 Clinical Development of a Single-shot Live-attenuated
